Dorte Strobaek
Ballerup, 2750, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Retroviral glycoprotein-mediated immune suppression via the potassium channel KCa3.1 - A new strategy for amelioration of inflammatory bowel diseases.
Journal: Clinical immunology (Orlando, Fla.)
Published: April 21, 2022
Quantification of the functional expression of the Ca2+ -activated K+ channel KCa 3.1 on microglia from adult human neocortical tissue.
Journal: Glia
Published: March 28, 2016
A pharmacological assessment of agonists and modulators at α4β2γ2 and α4β2δ GABAA receptors: The challenge in comparing apples with oranges.
Journal: Pharmacological research
Published: February 26, 2016
NS19504: a novel BK channel activator with relaxing effect on bladder smooth muscle spontaneous phasic contractions.
Journal: The Journal of pharmacology and experimental therapeutics
Published: June 22, 2014
Kv7 channels as targets for anti-epileptic and psychiatric drug-development.
Journal: European journal of pharmacology
Published: November 06, 2013
Biophysical and pharmacological characterization of α6-containing nicotinic acetylcholine receptors expressed in HEK293 cells.
Journal: Brain research
Published: August 03, 2013
Characterization of a novel high-potency positive modulator of K(v)7 channels.
Journal: European journal of pharmacology
Published: January 15, 2013
A high-throughput screening campaign for detection of ca(2+)-activated k(+) channel activators and inhibitors using a fluorometric imaging plate reader-based tl(+)-influx assay.
Journal: Assay and drug development technologies
Published: December 04, 2012
Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2.
Journal: Chemistry & biology
Published: May 01, 2012
NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.
Journal: British journal of pharmacology
Published: February 21, 2012
CyPPA, a Positive SK3/SK2 Modulator, Reduces Activity of Dopaminergic Neurons, Inhibits Dopamine Release, and Counteracts Hyperdopaminergic Behaviors Induced by Methylphenidate.
Journal: Frontiers in pharmacology
Published: December 20, 2011
Evidence for a common pharmacological interaction site on K(Ca)2 channels providing both selective activation and selective inhibition of the human K(Ca)2.1 subtype.
Journal: Molecular pharmacology
Published: November 03, 2011
Showing 1-12 of 12
Last Updated: 09/26/2026